000			01484 a2200433 4500
005			20250516122034.0
264		0	_c20130826
008			201308s 0 0 ger d
022			_a1433-0563
024	7		_a10.1007/s00120-012-3054-8 _2doi
040			_aNLM _beng _cNLM
100	1		_aMerseburger, A S
245	0	0	_a[Pathophysiology and therapy of castration-resistant prostate cancer]. _h[electronic resource]
260			_bDer Urologe. Ausg. A _cFeb 2013
300			_a219-25 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAndrogen Antagonists _xadverse effects
650	0	4	_aAndrostenes
650	0	4	_aAndrostenols _xadverse effects
650	0	4	_aAntineoplastic Agents, Hormonal _xadverse effects
650	0	4	_aBenzamides
650	0	4	_aBiomarkers, Tumor _xblood
650	0	4	_aDisease Progression
650	0	4	_aDrug Resistance, Neoplasm
650	0	4	_aHumans
650	0	4	_aImidazoles _xadverse effects
650	0	4	_aMale
650	0	4	_aNaphthalenes _xadverse effects
650	0	4	_aNitriles
650	0	4	_aOrchiectomy
650	0	4	_aPhenylthiohydantoin _xadverse effects
650	0	4	_aProstate _xdrug effects
650	0	4	_aProstate-Specific Antigen _xblood
650	0	4	_aProstatic Neoplasms _xdrug therapy
700	1		_aKuczyk, M A
700	1		_aWolff, J M
773	0		_tDer Urologe. Ausg. A _gvol. 52 _gno. 2 _gp. 219-25
856	4	0	_uhttps://doi.org/10.1007/s00120-012-3054-8 _zAvailable from publisher's website
999			_c22272360 _d22272360